46results about How to "Increase in motility" patented technology

The present invention relates to a system and method for determining sleep, sleep stage and / or sleep stage transition of a person, including heart rate detecting means configured for detecting a heart rate of the person, movement detecting means configured for detecting a movement of a part of the body of the person, where the detected movement is caused by a skeletal muscle of the body, recording means configured for recording the detected heart rate and the detected movement of the part of the body, heart rate classifying means configured for classifying the recorded heart rate of the person into at least one heart rate class at least one heart rate variability class, movement classifying means configured for classifying the recorded movement into at least one movement class, and determining means configured for determining sleep, a sleep stage, a sleep stage transition and / or a sleep event of the person based at least partially on the at least one heart rate class and the at least one movement class.

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

A method of promoting the healing of a lesion in a smooth muscle, comprising selecting a smooth muscle portion having a lesion and applying a non-excitatory electrical field to the portion, which field reduces the mechanical activity of the portion.

The present invention relates to stem cells which exhibit increased sensitivity to a chemoattractant and, more particularly, to methods of generating and using them such as in clinical applications involving stem cell transplantation.

The present invention relates to a system and method for determining sleep, sleep stage and / or sleep stage transition of a person, including heart rate detecting means configured for detecting a heart rate of the person, movement detecting means configured for detecting a movement of a part of the body of the person, where the detected movement is caused by a skeletal muscle of the body, recording means configured for recording the detected heart rate and the detected movement of the part of the body, heart rate classifying means configured for classifying the recorded heart rate of the person into at least one heart rate class at least one heart rate variability class, movement classifying means configured for classifying the recorded movement into at least one movement class, and determining means configured for determining sleep, a sleep stage, a sleep stage transition and / or a sleep event of the person based at least partially on the at least one heart rate class and the at least one movement class.

The present invention provides a composition including a polar organic extract of Eurycoma longifolia and a fraction derived from the polar organic extract, said composition comprising of quassinoids, coumarins, their glycosides, analogues and derivatives, which exhibits bioactivity of increasing spermatozoa production and spermatozoa quality in terms of morphology and motility, as well as increasing testosterone synthesis and release from cells of males. The extraction method of E. longifolia plant to produce the polar organic extract, and the subsequent purification to produce the fraction of polar organic extract containing the quassinoids, coumarins, their glycosides, analogues and derivatives, and uses for manufacturing a preparation for infertility treatment are also provided. The fraction of polar organic extract containing the quassinoids, coumarins, their glycosides, analogues and derivatives is formulated for medical applications via several routes of administration.

A pharmaceutical composition is provided for use in the healing of cells containing about 0.0001 percent weight per volume (% w / v) to about 2% w / v of an alginic acid or a salt of alginic acid having a molecular weight in the range of greater than about 250,000 to about 1,000,000, provided that if the composition additionally contains an alginic acid or a salt of alginic acid having a molecular weight in the range of about 20,000 to about 250,000, it is present in an amount of less than 1% w / w. The use of the pharmaceutical composition for the healing cells in a mammal, preferably mucosal cells is also provided.

The present invention concerns a method for the treatment of inflammatory arthritis, and in particular rheumatoid arthritis, by administering to the subject specific low dosages of N6-(3-iodobenzyl)-adenosine 5′-N-methyl-uronamide (IB-MECA) and 2-chloro-N6-(3-iodobenzyl)-adenosine-5′-N-methyl-uronamide (CL-IB-MECA).

Disclosed herein are methods, compositions and kits for treating cardiac stem cells to be administered to a subject in need thereof, e.g., with a damaged myocardium. The methods, composition and kits of the invention can be used to treat cardiovascular diseases such as heart failure, myocardial infarction and an age-related cardiomyopathy.

A quasi-spherical orbital implant that comprises an off center conical elongation toward its posterior and medial aspects. The conical elongation mimics the natural shape of an orbit. The implant comprises a number of holes and tunnels for suturing the patient's eye muscles and tissue to the implant. A number of hollow voids in the implant serve to progressively host the formation of tissue which secures the implant to the muscles and covering tissue and helps to prevent migration after the sutures have dissolved. The anterior portion of the implant has a number of details which key with the prosthetic eye and help improve its stability and motility.

The present invention provides a composition including a polar organic extract of Eurycoma longifolia and a fraction derived from the polar organic extract, said composition comprising of quassinoids, coumarins, their glycosides, analogues and derivatives, which exhibits bioactivity of increasing spermatozoa production and spermatozoa quality in terms of morphology and motility, as well as increasing testosterone synthesis and release from cells of males. The extraction method of E. longifolia plant to produce the polar organic extract, and the subsequent purification to produce the fraction of polar organic extract containing the quassinoids, coumarins, their glycosides, analogues and derivatives, and uses for manufacturing a preparation for infertility treatment are also provided. The fraction of polar organic extract containing the quassinoids, coumarins, their glycosides, analogues and derivatives is formulated for medical applications via several routes of administration.

The present invention provides new uroguanylin derivatives that are useful for the treatment of gastrointestinal disorders. The present invention also provides compositions and methods of treating gastrointestinal disorders and pharmaceutical compositions for accomplishing the same. In some embodiments, these pharmaceutical compositions include oral dosage forms.

Sperm Delivery Device with a cup shaped sperm storage vessel, the side walls of the vessel having plurality of retaining receptacles, a resilient disk shaped portion integral with and parallel to the base of the sperm storage vessel, a thin closure membrane that dissolves at body temperature in a moist environment, and a closure ring having downwardly extending prongs that penetrate the retaining receptacles of said side walls of said sperm storage vessel that traps said closure membrane between the top of said sperm containing vessel and the underside of said closure ring. A preferred embodiment includes wherein said dissolvable closure sheet is made of gelatin or some other non-harmful dissolvable ingredient.

Disclosed is a method for screening a novel cancer therapeutic agent. The cancer therapeutic agent exhibits down-regulation of galectin-3 and fascin-1 or interferes with the interaction between galectin-3 and GSK-3β.